Baudax Bio Inc. (BXRX) PT Lowered to $2 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Baudax Bio Reports First Quarter 2021 Financial Results
May 5, 2021 7:00 AM EDTANJESO® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q420
Average Sales per Account Increased 30% in Q1 compared to Q420
Richard S. Casten Strengthens Management Team in Chief Financial Officer Role
Management to Host Investor Conference Call and Webcast Today at 8:00 a.m. ET
MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ: BXRX) (the Company), a pharmaceutical company focused on developing and commercializing innovative... More
